
SPECIAL REPORT | LIFE SCIENCES | MILAN
The Full Stack, Humanised
Talent. Research. Clinical excellence. Industrial capacity. A city where science moves at the speed of collaboration.
MILAN | May 2026
The life-sciences investor’s checklist is notoriously long. A credible city needs world-class universities to generate talent. It needs research hospitals capable of running complex clinical trials. It needs venture capital willing to back early-stage science. It needs manufacturing infrastructure that can translate discovery into product. And, increasingly, it needs to offer something harder to quantify: a social and professional ecosystem able to attract—and retain—the scientists, physicians, entrepreneurs and innovators who shape the future of medicine.
Most cities manage two or three of these ingredients. A handful manage most. Milan, quietly and with increasing confidence, is assembling all of them into a coherent system. But the city’s advantage is not simply the presence of excellent institutions. It is the density of interaction among them.
Milan has long represented a unique model of integration within the Italian landscape: an ecosystem in which scientific excellence, industrial capability, clinical care and social dynamism coexist in a productive equilibrium. In life sciences, this integration has evolved into what could almost be described as a modern ius laboris: a system in which talent, competence and the capacity to contribute to innovation become the true drivers of inclusion and growth.
This is Milan’s rarely advertised advantage: not only the presence of world-class assets, but their physical and operational proximity.
CLOSE ENOUGH TO MATTER
In life sciences, geography still governs speed. The distance between a research laboratory, a clinical trial site, a contract manufacturer and a venture investor is not merely logistical—it is a structural tax on innovation. Every institutional boundary adds friction, time and cost.
This is Milan’s rarely advertised advantage: not only the presence of world-class assets, but their physical and operational proximity. Within a metropolitan radius that can be crossed in under an hour, the city boasts 20 research hospitals belonging to a national network of excellence (IRCCS)—the highest concentration in Europe—together with private and public universities, biotech companies, pharmaceutical manufacturing, venture capital, and technology-transfer networks.
The European Institute of Oncology, Humanitas, San Raffaele, Galeazzi-Sant’Ambrogio and Centro Cardiologico Monzino are not simply prestigious names. They are active engines of translational medicine, collectively accounting for more than half of Italy’s pharmacological clinical trials. Six of Italy’s nine authorised cell and gene therapy factories are located in Lombardy. The pharmaceutical manufacturing base—among Europe’s largest—is embedded within the same industrial fabric.
A startup developing a molecule inside Milan’s innovation ecosystem is not separated from clinical validation or industrial production by multiple flights and disconnected supply chains. In many cases, those capabilities exist within the same district—or ten minutes down the road.
Professor Giulio Pompilio, scientific director of Centro Cardiologico Monzino IRCCS, has spent more than three decades working at the intersection of cardiac surgery, translational research, regenerative medicine and advanced therapies. He describes Milan’s model as unique in the European panorama, precisely because research excellence and clinical care are not separate domains.
“At Monzino, advanced scientific research is inseparable from highly specialised patient care,” he explains. “The proximity between translational laboratories and clinical practice accelerates the development of new therapies, precision medicine approaches, digital health solutions and preventive strategies. This virtuous cycle improves patient outcomes while simultaneously generating knowledge, intellectual property and new professional opportunities.”
That model, replicated across multiple institutions within a single metropolitan area, is what transforms Milan from a collection of excellent hospitals into a functioning ecosystem.

THE STACK, CONNECTED
The assets filling this ecosystem are increasingly visible internationally. Human Technopole, established within MIND—the Milano Innovation District created on the former Expo 2015 site—has rapidly become one of Europe’s most ambitious scientific hubs, assembling more than 500 researchers from over 40 nationalities, and building national facilities dedicated to genomics, structural biology and advanced computational biology.
What distinguishes MIND is not only the concentration of institutions, but the collaborative model underpinning them. Human Technopole, the new University of Milan scientific campus, IRCCS Galeazzi-Sant’Ambrogio, pharma and biotech companies, digital health startups, investors, and multinational corporations operate within a shared innovation platform designed to accelerate translational research and technology transfer.
In this sense, MIND embodies Milan’s broader life-sciences identity: open, international, interdisciplinary and operationally integrated. Researchers, clinicians, engineers, entrepreneurs and policymakers interact within the same ecosystem, allowing ideas to move rapidly from laboratory to bedside and from proof-of-concept to industrial application.
In October 2026, more than 62,000 delegates from 166 countries will gather at Fiera Milano for CPHI, the world’s largest pharmaceutical trade event. Weeks earlier, in June, WOMA will open its doors in the same city, with CRISPR pioneer and Nobel laureate Jennifer Doudna making her Italian debut.
These events do not choose Milan for its exhibition space alone. As Tara Dougal, Event Director for the pharma portfolio at Informa Markets, notes: “For us as global organisers, Milan’s complete ecosystem—spanning talent, research, and production—plays a key role in the success of an event of this scale. Lombardy’s position as home to a third of Italy’s life sciences enterprises creates an environment where ideas and partnerships can grow.”
The city’s talent pipeline reflects this density. Eight universities, more than 200,000 students, internationally oriented graduate programmes and increasing institutional collaboration have turned Milan into Italy’s primary magnet for scientific and biomedical talent. The ecosystem is reinforced by industrial depth: pharmaceutical production, APIs, biologics manufacturing, packaging, medtech and regulatory expertise coexist within the same regional supply chain.
What separates Milan from younger, more speculative innovation clusters is that it is not merely projecting future potential. Its industrial and scientific foundations are already operational.
ALREADY INDUSTRIALISED
What separates Milan from younger, more speculative innovation clusters is that it is not merely projecting future potential. Its industrial and scientific foundations are already operational.
The IRCCS network is the product of decades of institutional development. The pharmaceutical ecosystem employs hundreds of thousands of people across manufacturing, research, logistics and advanced services. Venture capital has increasingly followed the science, while fiscal incentives and internationalisation policies have improved the city’s competitiveness for global talent and investment.
But Milan’s greatest strength may be cultural rather than structural. The city combines scientific ambition with a deeply rooted operational pragmatism. Researchers and innovators find not only world-class infrastructure and clinical data, but also an environment able to translate discovery into impact with unusual speed.
Patients, meanwhile, benefit from a healthcare system in which cutting-edge science is embedded directly within high-quality care delivery.

THE VERDICT
Global competition for scientific talent is intensifying. Cities everywhere are trying to position themselves as innovation hubs. Yet few manage to connect research, healthcare, manufacturing, education and investment into a genuinely integrated metropolitan ecosystem.
Milan increasingly does.
What peer ecosystems in Basel, Cambridge or Munich understand—and what the international life-sciences sector is beginning to recognise—is that Milan’s advantage was not created through a single masterplan. It emerged through decades of institutional density, industrial tradition, scientific excellence and a metropolitan scale where all parts of the value chain remain within easy reach of one another.
This is why Milan has become not only Italy’s leading life-sciences ecosystem, but an increasingly relevant international hub for biomedical research, advanced therapies, healthcare innovation and clinical excellence.
The full stack is assembled. But more importantly, the system is connected.
CONNECT WITH MILAN
Milano & Partners’ FDI team supports international companies, research institutions and investors looking to establish or expand a presence in Milan. Services are provided free of charge and cover location analysis, regulatory orientation, talent access and stakeholder introductions.
To get in touch, complete the enquiry form at business.yesmilano.it or meet the team in person at the following events.
Upcoming events
BIO International Convention — San Diego Convention Center | San Diego, 22-25 June 2026 WOMA — WOrld of PharMA — Allianz MiCo | Milan, 25-26 June 2026 CPHI Worldwide — Fiera Milano | Milan, 6-8 October 2026
